Migraine in Women
- PMID: 29270933
- DOI: 10.1055/s-0037-1607393
Migraine in Women
Abstract
Migraine is one of the most common neurological disorders, affecting women disproportionally at a rate of 3:1. Prior to puberty, boys and girls are equally affected, but the female preponderance emerges after puberty. Migraine pathophysiology is not fully understood, and although the hormonal effect of estrogen is significant, other factors are at play. This article will focus on the hormonal influence on migraine in women. Here we review our most recent understanding of migraine and menstrual migraine, including epidemiology, pathophysiology, and treatment strategies for this challenging disorder, as well as migraine during pregnancy, postpartum period, breastfeeding, perimenopause, and menopause. We also review the risks and benefits of exogenous hormone use in this population and discuss stroke risk in women with migraine aura. By understanding these aspects of migraine in women, we hope to arm practitioners with the knowledge and tools to help guide treatment of this debilitating disorder in this large population.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Conflict of interest statement
Conflict of Interest: Dr Broner reports personal fees from Allergan, outside the submitted work.
Similar articles
-
Migraine in women.Neurol Clin. 2009 May;27(2):503-11. doi: 10.1016/j.ncl.2009.01.002. Neurol Clin. 2009. PMID: 19289228 Review.
-
Migraine and perimenopause.Maturitas. 2014 Aug;78(4):277-80. doi: 10.1016/j.maturitas.2014.05.018. Epub 2014 Jun 2. Maturitas. 2014. PMID: 24954701 Review.
-
Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review.Headache. 2020 Jan;60(1):200-216. doi: 10.1111/head.13665. Epub 2019 Oct 3. Headache. 2020. PMID: 31579938 Review.
-
Hormonal factors in migraine: a population-based study of women aged 40 to 74 years.Headache. 2003 Jan;43(1):27-35. doi: 10.1046/j.1526-4610.2003.03005.x. Headache. 2003. PMID: 12864755
-
Hormonal changes throughout life in women.Headache. 2006 Oct;46 Suppl 2:S49-54. doi: 10.1111/j.1526-4610.2006.00554.x. Headache. 2006. PMID: 17044841 Review.
Cited by
-
Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.Front Pharmacol. 2024 Jan 9;14:1257282. doi: 10.3389/fphar.2023.1257282. eCollection 2023. Front Pharmacol. 2024. PMID: 38264523 Free PMC article.
-
Association between sleep quality, migraine and migraine burden.Front Neurol. 2022 Aug 26;13:955298. doi: 10.3389/fneur.2022.955298. eCollection 2022. Front Neurol. 2022. PMID: 36090858 Free PMC article.
-
Health-related quality of life and associated factors in Chinese menstrual migraine patients: a cross-sectional study.BMC Womens Health. 2022 May 15;22(1):177. doi: 10.1186/s12905-022-01760-8. BMC Womens Health. 2022. PMID: 35570288 Free PMC article. Clinical Trial.
-
Prolactin signaling modulates stress-induced behavioral responses in a preclinical mouse model of migraine.Headache. 2022 Jan;62(1):11-25. doi: 10.1111/head.14248. Epub 2021 Dec 29. Headache. 2022. PMID: 34967003 Free PMC article.
-
Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation.J Headache Pain. 2018 Aug 14;19(1):68. doi: 10.1186/s10194-018-0898-3. J Headache Pain. 2018. PMID: 30109437 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous